Citations

Clear

3942 citation(s) found for "To, Van".

Evaluating the Impact of Breast and Nipple Sensation on Quality-of-Life after Nipple-sparing Mastectomy with Implant Reconstruction: Long-term Outcomes Utilizing Breast-Q
Spronsen, Nicole R Van, Armstrong, Valerie, Rebecca, Alanna M. , Casey, William J., Kruger, Erwin A., Pockaj, Barbara A. , Teven, Chad M. , Spronsen, Nicole Van , Hammond, Jacob B. , Kandi, Lyndsay A. , Kosiorek, Heidi , Cronin, Patricia A

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | December 7, 2022 | Volume: 10 | Issue: 11S | Pages: 1-2

10.1097/01.gox.0000905076.77838.ec Get It

Abstract A010: Molecular characteristics and prognosis of early-onset colorectal cancer according to detailed anatomical locations: Comparison to later-onset cases
Gallinger, Steven , Pai, Rish K. , Pellatt, Andrew J. , Woods, Michael O. , Phipps, Amanda I. , Peters, Ulrike , Pellatt, Andrew J , Ugai, Tomotaka , Cao, Yin , Haruki, Koichiro , Harrison, Tabitha A. , Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Gunter, Marc J. , Hoffmeister, Michael , Jenkins, Mark A. , Milne, Roger L. , Newcomb, Polly A. , Schoen, Robert E. , Guelpen, Bethany Van , Ogino, Shuji

Mayo Clinic

Cancer Research | December 2, 2022 | Volume: 82 | Issue: 23_Supplement_1 | Pages: A010-A010

10.1158/1538-7445.crc22-a010 Get It

Abstract Background: Evidence suggests that, compared to later-onset colorectal cancer (CRC), early-onset CRC (diagnosed before 50 years of age) occur more frequently in rectal location and less frequently in proximal colon location. Studies also indicate heterogeneity of molecular characteristics within early-onset CRCs and between early-onset and later-onset CRCs. Understanding how tumor molecular features and biological aggressiveness of early-onset CRC differ by detailed tumor location is important in personalized patient management. Methods: Using 14,004 CRC cases including 3,089 early-onset cases from The Cancer Genome Atlas and the Genetics and Epidemiology of CRC Consortium (GECCO), we examined microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and KRAS and BRAF mutations in cancers of the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum. We further conducted CRC-specific survival analyses of detailed tumor location stratified by molecular characteristics using multivariable Cox proportional hazards models. Results: The proportions of MSI-high, CIMP-high, and BRAF-mutated early-onset tumors gradually increased from the rectum (8.8%, 3.4%, and 3.5%, respectively) to the ascending colon (46% MSI-high; 15% CIMP-high) or transverse colon (8.6% BRAF-mutated), followed by declines in the cecum for MSI-high (36%) and BRAF-mutated (4.6%) tumors. Notably, later-onset MSI-high tumors showed a continuous decrease in KRAS mutation prevalence from the rectum (36%) to ascending colon (9%; Ptrend <0.001) followed by an increase in the cecum (14%), while early-onset MSI-high cancer showed no such trend. In survival analyses, there was a trend for better CRC-specific survival from the cecum to sigmoid colon (Ptrend<0.001) (but not to rectum), which did not significantly differ by age of diagnosis (Pinteraction=0.61). Multivariable-adjusted hazard ratios (HRs) for sigmoid vs. cecum were 0.86 (95% CI, 0.64-1.14) for early-onset cases and 0.81 (95% CI, 0.70-0.93) for later-onset cases. Notably, the prognostic association of tumor location differed by MSI status (Pinteraction=0.001). Non-MSI-high tumors exhibited the cecum-to-sigmoid trend for better CRC-specific survival [Ptrend <0.001; multivariable-adjusted HR for the sigmoid colon (vs. cecum), 0.80; 95% CI, 0.70-0.92], whereas MSI-high tumors demonstrated an opposite cecum-to-sigmoid trend for worse survival (Ptrend = 0.020; the corresponding HR, 2.13; 95% CI, 1.15-3.92). Conclusions: Our findings support biogeographical and pathogenic heterogeneity of CRC in different age groups and colorectal subsites. Both detailed colorectal location and tumor molecular features need to be accounted for prognostication of early-onset and later-onset CRCs to advance precision medicine. Citation Format: Tomotaka Ugai, Yin Cao, Koichiro Haruki, Tabitha A. Harrison, Daniel D. Buchanan, Peter T. Campbell, Andrew T. Chan, Steven Gallinger, Marc J. Gunter, Michael Hoffmeister, Mark A. Jenkins, Roger L. Milne, Polly A. Newcomb, Rish K. Pai, Andrew J. Pellatt, Robert E. Schoen, Bethany Van Guelpen, Michael O. Woods, Amanda I. Phipps, Ulrike Peters, Shuji Ogino. Molecular characteristics and prognosis of early-onset colorectal cancer according to detailed anatomical locations: Comparison to later-onset cases [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1):Abstract nr A010.
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M. , Berg, David D. , Bohula, Erin A. , Baird-Zars, Vivian M., Barnett, Christopher F. , Barsness, Gregory W. , Chaudhry, Sunit‐Preet , Daniels, Lori B. , Diepen, Sean van , Goldfarb, Michael , Katz, Jason N. , Kenigsberg, Benjamin B. , Lawler, Patrick R. , Miller, P. Elliott , Papolos, Alexander , Park, Jeong‐Gun , Prasad, Rajnish, Teuteberg, Jeffrey J. , Investigators, on behalf of the CCCTN, Goldfarb, Michael , van Diepen, Sean , Goldfarb, Michael , Jentzer, Jacob C , Lawler, Patrick , Miller, P Elliott , Potter, Brian J , Singam, N Sarma V , Solomon, Michael A , Teuteberg, Jeffrey J , Morrow, David A , Goldfarb, Michael , Daniels, Lori B , Bohula, Erin A , Berg, David , Patel, Siddharth M , Ghafghazi, Shahab , Jentzer, Jacob C. , Prasad, Rajnish, Singam, Narayana Sarma V. , Sinha, Shashank S , Solomon, Michael A. , Morrow, David A. , Investigators, on behalf of the CCCTN

Mayo Clinic

Circulation: Heart Failure | December 2, 2022 | Volume: 16 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.122.009714 | PMID 36458542 Get It

Background: Algorithmic application of the 2019 Society of Cardiovascular Angiography and Intervention (SCAI) shock stages effectively stratifies mortality risk for patients with cardiogenic shock. However, clinician assessment of SCAI staging may differ. Moreover, the implications of the 2022 SCAI criteria update remain incompletely defined. Methods: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units (CICUs). Between 2019 and 2021, participating centers (n=32) contributed at least a 2-month snapshot of consecutive medical CICU admissions. In-hospital mortality was assessed across 3 separate staging methods: clinician assessment, Critical Care Cardiology Trials Network algorithmic application of the 2019 SCAI criteria, and a revision of the Critical Care Cardiology Trials Network application using the 2022 SCAI criteria. Results: Of 9612 admissions, 1340 (13.9%) presented with cardiogenic shock with in-hospital mortality of 35.2%. Both clinician and algorithm-based staging using the 2019 SCAI criteria identified a stepwise gradient of mortality risk (stage C–E: 19.0% to 83.7% and 14.6% to 52.2%, respectively; P trend <0.001 for each). Clinician assignment of SCAI stages identified higher risk patients compared with algorithm-based assignment (stage D: 49.9% versus 29.3%; stage E: 83.7% versus 52.2%). Algorithmic application of the 2022 SCAI criteria, with incorporation of the vasoactive-inotropic score, more closely approximated clinician staging (mortality for stage C-E: 21.9% to 70.5%; P trend <0.001). Conclusions: Both clinician and algorithm-based application of the 2019 SCAI stages identify a stepwise gradient of mortality risk, although clinician-staging may better allocate higher risk patients into advanced SCAI stages. Updated algorithmic staging using the 2022 SCAI criteria and vasoactive-inotropic score further refines risk stratification.
ASHP Foundation Pharmacy Forecast 2023: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems
Nesbit, Todd, Reuland, Charles, Cunningham, Francesca , Schweitzer, Pamela, Chisholm‐Burns, Marie A., Martinez, Leyner, Shane, Rita , Scott, Christopher M., Nelson, Scott D. , Mize, Dara, Devender, Elva Angelique Van, Oyen, Lance J., Nelson, Scott D. , Oyen, Lance, DiPiro, Joseph T. , Chisholm‐Burns, Marie A. , Nelson, Scott D

Mayo Clinic

American Journal of Health-System Pharmacy | December 1, 2022 | Volume: 80 | Issue: 2 | Pages: 10-35

10.1093/ajhp/zxac274 | PMID 36450306 Get It

Barriers to Implementation of Contrast-Enhanced Mammography in Clinical Practice: AJR Expert Panel Narrative Review
Cozzi, Andrea , Zuley, Margarita L. , Nijnatten, Thiemo J. A. van , Lobbes, Marc B. I. , Patel, Bhavika , Jochelson, Maxine S.

Mayo Clinic

American Journal of Roentgenology | November 30, 2022 | Volume: 221 | Issue: 1 | Pages: 3-6

10.2214/ajr.22.28567 | PMID 36448912 Get It

Prevalence, pathophysiology, prediction and health-related quality of life of long COVID: study protocol of the longitudinal multiple cohort CORona Follow Up (CORFU) study
Ghossein‐Doha, Chahinda , Wintjens, Marieke S. J. N. , Janssen, Emma B N J , Klein, Dorthe O. , Heemskerk, Stella C M , Asselbergs, Folkert W. , Birnie, Erwin , Bonsel, Gouke J. , Bussel, Bas C. T. van , Cals, Jochen , Haagsma, Juanita A. , Hemmen, Bena , Kietselaer, Bas , Linschoten, Marijke , Santen, Susanne van, Vernooy, Kevin , Willems, Loes H. , Westerborg, Rosa, Warlé, Michiel C. , Klein, Dorthe , van Bussel, Bas C T , Cals, Jochen W L , van der Horst, Iwan C C , Kietselaer, Bastiaan L J H, van Kuijk, Sander M J , Kietselaer, Bas L J H , Cate, Hugo Ten , Klok, Frederikus Albertus , Kruif, Martijn D. de

Mayo Clinic

BMJ Open | November 29, 2022 | Volume: 12 | Issue: 11 | Pages: e065142

10.1136/bmjopen-2022-065142 | PMID 36446465 Get It

Introduction The variety, time patterns and long-term prognosis of persistent COVID-19 symptoms (long COVID-19) in patients who suffered from mild to severe acute COVID-19 are incompletely understood. Cohort studies will be combined to describe the prevalence of long COVID-19 symptoms, and to explore the pathophysiological mechanisms and impact on health-related quality of life. A prediction model for long COVID-19 will be developed and internally validated to guide care in future patients. Methods and analysis Data from seven COVID-19 cohorts will be aggregated in the longitudinal multiple cohort CORona Follow Up (CORFU) study. CORFU includes Dutch patients who suffered from COVID-19 at home, were hospitalised without or with intensive care unit treatment, needed inpatient or outpatient rehabilitation and controls who did not suffer from COVID-19. Individual cohort study designs were aligned and follow-up has been synchronised. Cohort participants will be followed up for a maximum of 24 months after acute infection. Next to the clinical characteristics measured in individual cohorts, the CORFU questionnaire on long COVID-19 outcomes and determinants will be administered digitally at 3, 6, 12, 18 and 24 months after the infection. The primary outcome is the prevalence of long COVID-19 symptoms up to 2 years after acute infection. Secondary outcomes are health-related quality of life (eg, EQ-5D), physical functioning, and the prevalence of thromboembolic complications, respiratory complications, cardiovascular diseases and endothelial dysfunction. A prediction model and a patient platform prototype will be developed. Ethics and dissemination Approval was obtained from the medical research ethics committee of Maastricht University Medical Center+ and Maastricht University (METC 2021-2990) and local committees of the participating cohorts. The project is supported by ZonMW and EuroQol Research Foundation. Results will be published in open access peer-reviewed scientific journals and presented at (inter)national conferences. Trial registration number NCT05240742 .
Risk of Parathyromatosis after Fine-Needle Aspiration
Kendrick, Michael L. , Charboneau, J. William, Curlee, Kathleen J. , Heerden, Jon A. van, Farley, David R.

Mayo Clinic

The American Surgeon | November 29, 2022 | Volume: 67 | Issue: 3 | Pages: 290-294

10.1177/000313480106700317 Get It

Reoperative surgery for hyperparathyroidism (HPT) is fraught with hazard. When preoperative imaging studies are inconclusive or patient comorbidities are extensive fine needle-aspiration (FNA) is helpful to confirm the presence of suspected parathyroid tissue in the neck. Some surgeons refrain from using FNA because of the concern of tissue implantation (parathyromatosis). A retrospective review (1984–1996) of all patients diagnosed with HPT undergoing FNA of suspected parathyroid tissue was performed to document whether a correlation exists between FNA of suspected parathyroid tissue and subsequent development of parathyromatosis. Parathyromatosis was considered to have occurred when proven by histology or suspected on the basis of clinical studies. Of 81 patients with HPT undergoing ultrasound-guided FNA to assess abnormalities in the neck 41 patients with confirmed parathyroid tissue were identified. The indications for FNA in these 41 patients were: prior failed cervical exploration (n = 33), prior neck surgery and/or radiation (n = 2), inconclusive noninvasive imaging studies (n = 15), and severe comorbidities (n = 8). Mean follow-up was 5.8 years. No case of FNA-induced parathyromatosis was identified. FNA is useful to confirm the presence of parathyroid tissue in very select patients with hyperparathyroidism. FNA often eliminates the need for other imaging studies, may prevent a needless or likely fruitless re-exploration, and does not cause parathyromatosis.
Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma
Ahmed, Salsabil, Wiesen, Lisa, Sharma, Neeraj , Mukherjee, Ujjal Kumar , Kumar, Shaji , Ness, Brian G. Van , Sharma, Neeraj , Mazumder, Suman , Baughn, Linda B. , Mitra, Amit

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4249-4250

10.1182/blood-2022-164501 Get It

Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations
He, Rong , Hampel, Paul J. , Call, Timothy G. , Koehler, Amber B. , Behnken, Amy, Leis, José F., Viswanatha, David S., Dyke, Daniel L. Van , Hwang, Steven R. , Wang, Yucai , Rabe, Kari G. , Kenderian, Saad S. , Muchtar, Eli , Kay, Neil E. , Braggio, Esteban , Shi, Min , Slager, Susan L. , Parikh, Sameer A. , Ding, Wei

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12390-12392

10.1182/blood-2022-165508 Get It